Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mangafodipir - PledPharma

Drug Profile

Mangafodipir - PledPharma

Alternative Names: mangafodipir trisodium; MnDPDP; PP-099; S 095; Teslascan; WIN 59010

Latest Information Update: 03 Mar 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GE Healthcare
  • Developer GE Healthcare; PledPharma
  • Class Acetates; Anti-ischaemics; Contrast media; Ethylenediamines; Pyridines; Small molecules
  • Mechanism of Action Antioxidants; Iron chelating agents; Magnetic resonance imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Myocardial infarction
  • Market Withdrawal Liver disorders
  • Discontinued Neutropenia

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 29 Feb 2016 PledPharm receives patent for PLED compounds for their anti-cancer effect by the European Patent Office
  • 29 Feb 2016 PledPharm receives use patent for PLED compounds by authorities in Canada, Russia, Mexico, Japan and Australia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top